Literature DB >> 11792884

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.

P A Klimiuk1, S Sierakowski, R Latosiewicz, B Cylwik, J Skowronski, J Chwiecko.   

Abstract

OBJECTIVE: Rheumatoid synovitis is characterized by an invasive and tissue-destructive infiltrate of lymphocytes, macrophages and synoviocytes. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) produced by these cells are important in the remodelling of the articular tissues in rheumatoid arthritis (RA). The aim of this study was to explore whether the serum concentrations of MMPs and their inhibitors were correlated with the histological appearance of the disease.
METHODS: Tissue and serum samples were obtained from 37 patients with clinically active RA and 30 with osteoarthritis (OA). Morphological analysis allowed the division of RA synovial specimens into two distinct types. In 22 samples only diffuse infiltrates of mononuclear cells without further microanatomical organization were found. In 15 specimens we observed lymphocytic conglomerates with germinal centre-like structures. Serum concentrations of interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase B (MMP-9), TIMP-1 and TIMP-2 were measured with an ELISA technique.
RESULTS: Unique serum profiles of MMPs and TIMPs were identified in each of the two histological types of RA synovitis. The serum concentrations of MMP-1, MMP-3 and MMP-9 were higher in RA patients than in OA patients used as a control group (P<0.001 for all comparisons). These three MMPs dominated in the serum of RA patients with follicular synovitis compared with those with diffuse synovitis (P<0.05, P<0.01 and P<0.001 respectively). The analysis of the serum concentrations of TIMP-1 and TIMP-2 showed that their levels were also elevated in RA patients compared with OA patients (P<0.001 and P<0.01 respectively). Only TIMP-1 was found in a significantly higher concentration in the serum of RA patients with follicular synovitis than in those with diffuse synovitis (P<0.05). The serum concentrations of MMPs and TIMP-1 clearly identified patients with two different histological types of rheumatoid synovitis and with OA. Additionally, the analysis of clinical data showed that the rheumatoid disease in patients with follicular synovitis seemed to be more active than in those with diffuse synovitis.
CONCLUSION: The morphological appearance of rheumatoid synovitis and the serum MMP and TIMP-1 profile were correlated with the clinical activity of the disease, confirming the heterogeneity of RA. These associations also suggest that patients with different histological forms of RA might require different treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792884     DOI: 10.1093/rheumatology/41.1.78

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1β-induced arthritis.

Authors:  M Das; J Lu; M Joseph; R Aggarwal; S Kanji; B K McMichael; B S Lee; S Agarwal; A Ray-Chaudhury; O H Iwenofu; P Kuppusamy; V J Pompili; M K Jain; H Das
Journal:  Curr Mol Med       Date:  2012-02       Impact factor: 2.222

2.  Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane.

Authors:  Tomoko Matsumoto; Toshiyuki Tsurumoto; Hiroyuki Shindo
Journal:  Rheumatol Int       Date:  2006-10       Impact factor: 2.631

3.  Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.

Authors:  Jelena Basic; Dusica Pavlovic; Tatjana Jevtovic-Stoimenov; Jelena Vojinovic; Gordana Susic; Ivana Stojanovic; Gordana Kocic; Vuk Milosevic; Tatjana Cvetkovic; Milena Marinkovic; Andrej Veljkovic
Journal:  J Physiol Biochem       Date:  2010-07-02       Impact factor: 4.158

4.  Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis.

Authors:  S Andereya; N Streich; B Schmidt-Rohlfing; T Mumme; R Müller-Rath; U Schneider
Journal:  Rheumatol Int       Date:  2005-07-06       Impact factor: 2.631

5.  Serum chemokines in patients with rheumatoid arthritis treated with etanercept.

Authors:  Piotr Adrian Klimiuk; Stanislaw Sierakowski; Izabela Domyslawska; Justyna Chwiecko
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

6.  Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy.

Authors:  Bashir M Mohamed; Conleth Feighery; Jacinta Kelly; Christian Coates; Una O'Shea; Louise Barnes; Mohamed Abuzakouk
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

7.  Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.

Authors:  Piotr Adrian Klimiuk; Jacek Kita; Justyna Chwiecko; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2008-07-29       Impact factor: 2.980

9.  Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population.

Authors:  H J Lee; G H Lee; S Nah; K H Lee; H Yang; Y M Kim; W Chun; S Hong; S Kim
Journal:  Rheumatol Int       Date:  2008-02-27       Impact factor: 2.631

Review 10.  The role of leukocyte-stromal interactions in chronic inflammatory joint disease.

Authors:  Angela Burman; Oliver Haworth; Paul Bradfield; Greg Parsonage; Andrew Filer; Andrew M C Thomas; Nicole Amft; Mike Salmon; Christopher D Buckley
Journal:  Joint Bone Spine       Date:  2005-01       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.